UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 20, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
000-55016 |
26-0690857 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
655 Montgomery Street, Suite 900
San Francisco, CA |
94111 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Items.
On
August 20, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing that the U.S.
Patent and Trademark Office (USPTO) issued U.S. Patent No. 9,115,208 entitled, “Dopaminergic Neuronal Survival-Promoting
Factors and Uses Thereof.” The patent covers additional intellectual property protection for MANF
(mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The patent covers compositions
of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.
A copy of the Company’s press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
|
|
|
99.1
|
|
Amarantus Bioscience Holdings, Inc. Press Release, dated August
20, 2015.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
Date: August 20, 2015 |
By: |
/s/ Gerald E. Commissiong |
|
Name: |
Gerald E. Commissiong |
|
Title: |
Chief Executive Officer |
Exhibit 99.1
Amarantus Announces Issuance of United
States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
SAN FRANCISCO, CA, and GENEVA, SWITZERLAND
– August 20, 2015 – Amarantus BioScience Holdings,
Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications
and neurology, announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 9,115,208 entitled, “Dopaminergic
Neuronal Survival-Promoting Factors and Uses Thereof.” The patent covers additional intellectual property protection
for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell
therapy. The patent covers compositions of matter and methods of use related to the Company's proprietary manufacturing process
for synthetic MANF and its administration.
"The issuance of this key patent
covering the proprietary compositions of matter and methods of use for MANF is very important to our intellectual property portfolio
as we works towards the submission of a U.S. investigational new drug application for MANF for the
treatment of retinitis pigmentosa over the course of the next 12-18 months,”
said Gerald E. Commissiong, President & CEO of Amarantus. “We continue to advance our pre-clinical research and development
programs for MANF in other orphan ophthalmological indications and in Parkinson's disease
and believe this patent is key to building a robust patent estate with the ultimate goal of realizing MANF’s full commercial
potential in high value indications.”
Native MANF is currently under development
for the treatment of orphan ocular indications, including retinitis pigmentosa (RP). Amarantus recently received both U.S.
and European orphan drug designation for MANF for the treatment of RP. In addition
to RP and Parkinson's disease, proof-of-concept preclinical models have also demonstrated that MANF proteins have the potential
to treat a wide range of other conditions, including retinal artery occlusion, diabetes, ischemic heart disease and other chronic
disorders.
About Mesencephalic-Astrocyte-derived
Neurotrophic Factor (MANF)
MANF (mesencephalic-astrocyte-derived
neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for
the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response.
By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist
the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property
around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF, a naturally-occurring protein
that reduces and prevents apoptosis (programmed cell death) in response to injury or disease, was discovered utilizing Amarantus'
proprietary PhenoGuard™ Protein Discovery Engine.
MANF's lead indication is retinitis pigmentosa,
and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently being pursued. Further
applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity
and certain other rare orphan diseases currently under evaluation.
About Amarantus BioScience Holdings,
Inc.
Amarantus BioScience Holdings (OTCQX: AMBS)
is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS’
Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's
disease levodopa-induced dyskinesia with the potential to expand into adult ADHD and Alzheimer’s aggression. The Company
has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug
designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing
to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived
neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa
(RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF’s discovery.
AMBS’ Diagnostics division owns the
rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients
with relapsing-remitting multiple sclerosis (RRMS), and has an exclusive worldwide license to the Lymphocyte Proliferation test
(LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of
Leipzig, and owns further intellectual property for the diagnosis of Parkinson's disease (NuroPro®).
For further information please visit www.Amarantus.com,
or connect with the Company on Facebook, LinkedIn,
Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical
information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results,
and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally
are identified by the words "believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions. Forward-looking statements are based on current
expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from
the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include,
but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates,
competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating
forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications
Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Source: Amarantus Bioscience Holdings,
Inc.
###
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024